Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial.

Schackman BR, Scott CA, Sax PE, Losina E, Wilkin TJ, McKinnon JE, Swindells S, Weinstein MC, Freedberg KA.

Clin Infect Dis. 2007 Oct 15;45(8):1062-70. Epub 2007 Sep 4.

2.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
3.

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.

Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, Godfrey C, Bastow B, Ray MG, Wang H, Coombs RW, McKinnon J, Mellors JW; AIDS Clinical Trials Group 5201 Study Team.

JAMA. 2006 Aug 16;296(7):806-14.

PMID:
16905786
4.

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.

Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, Horban A, Wirtz V, Odeshoo L, Van den Dungen M, Gruber C, Ledesma E; SWAN Study Group.

Clin Infect Dis. 2007 Jun 1;44(11):1484-92. Epub 2007 Apr 25.

PMID:
17479947
5.

The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa.

Schneider K, Nwizu C, Kaplan R, Anderson J, Wilson DP, Emery S, Cooper DA, Boyd MA.

PLoS One. 2013;8(2):e54435. doi: 10.1371/journal.pone.0054435. Epub 2013 Feb 15.

6.

The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.

Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE.

AIDS. 2008 Oct 1;22(15):2025-33. doi: 10.1097/QAD.0b013e3283103ce6.

7.
8.

The cost effectiveness of combination antiretroviral therapy for HIV disease.

Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ.

N Engl J Med. 2001 Mar 15;344(11):824-31.

9.
10.
11.

Potential for simplification of HIV treatment with boosted protease inhibitor monotherapy.

Reina E, San Miguel R, Larrea N, Garcia P, Napal V.

Int J Clin Pharm. 2012 Dec;34(6):911-6. doi: 10.1007/s11096-012-9692-5. Epub 2012 Sep 25.

PMID:
23007692
12.

Darunavir: a review of its use in the management of HIV infection in adults.

McKeage K, Perry CM, Keam SJ.

Drugs. 2009;69(4):477-503. doi: 10.2165/00003495-200969040-00007. Review.

PMID:
19323590
13.
14.

Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial.

Cook J, Dasbach E, Coplan P, Markson L, Yin D, Meibohm A, Nguyen BY, Chodakewitz J, Mellors J.

AIDS Res Hum Retroviruses. 1999 Apr 10;15(6):499-508.

PMID:
10221527
15.

HIV drug resistance surveillance for prioritizing treatment in resource-limited settings.

Walensky RP, Weinstein MC, Yazdanpanah Y, Losina E, Mercincavage LM, Touré S, Divi N, Anglaret X, Goldie SJ, Freedberg KA; CEPAC International Investigators.

AIDS. 2007 May 11;21(8):973-82.

16.

Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.

Mauskopf J, Brogan A, Martin S, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:83-105. doi: 10.2165/11587470-000000000-00000.

PMID:
21182346
17.

Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.

Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams E.

Cochrane Database Syst Rev. 2014 May 22;(5):CD004772. doi: 10.1002/14651858.CD004772.pub4. Review.

PMID:
24852077
18.

Hospitalizations and costs of treatment for protease inhibitor-based regimens in patients with very advanced HIV-infection (CD4 < 50/mm(3)).

Floridia M, Massella M, Bucciardini R, Perucci CA, Rossi L, Tomino C, Fragola V, Ricciardulli D, Galluzzo CM, Giannini G, Pirillo MF, Andreotti M, Mirra M, Vella S.

HIV Clin Trials. 2000 Sep-Oct;1(2):9-16.

PMID:
11590493
19.

US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.

Brogan A, Mauskopf J, Talbird SE, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:129-46. doi: 10.2165/11587490-000000000-00000.

PMID:
21182348
20.

Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.

Molina JM, Journot V, Morand-Joubert L, Yéni P, Rozenbaum W, Rancinan C, Fournier S, Morlat P, Palmer P, Dupont B, Goujard C, Dellamonica P, Collin F, Poizot-Martin I, Chene G; ALIZE (Agence Nationale de Recherches sur le SIDA 099) Study Team.

J Infect Dis. 2005 Mar 15;191(6):830-9. Epub 2005 Feb 10.

PMID:
15717256

Supplemental Content

Support Center